Ocrevus Market Report 2026

Ocrevus Market Overview

• The Ocrevus market growth in the historic period has been driven by improved understanding of multiple sclerosis pathology, approvals for disease-modifying therapies • Market expansion is supported by growing adoption of personalized ms treatment approaches, expansion of home and outpatient infusion services • Growth Driver: Impact Of Rising Multiple Sclerosis Cases On The Growth Of The Market • Market Trend: Regulatory Approvals As A Key Trend Driving Innovation In The Market • North America was the largest region in 2025.

The key promising market opportunities in the ocrevus market include: • Relapsing-Remitting Multiple Sclerosis (Segmentation By Clinical Indications) → Expected gain of $1.88 Billion • Primary Progressive Multiple Sclerosis (Segmentation By Clinical Indications) → Expected gain of $0.91 Billion

What Is Covered Under Ocrevus Market?

Ocrevus is a prescription monoclonal antibody used to treat relapsing forms of multiple sclerosis (RMS), including relapsing-remitting MS, active secondary progressive MS, and primary progressive MS (PPMS). It works by targeting and depleting CD20-positive B-cells, which are involved in the immune-mediated damage to nerve cells in MS. The main types of indications for ocrevus include relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Relapsing-remitting multiple sclerosis (RRMS) is a form of multiple sclerosis characterized by clearly defined episodes of neurological symptoms followed by periods of recovery. It is available in both liquid and tablet or capsule formulations and can be administered through oral and injectable routes. It is used by hospitals, retail pharmacies, and online pharmacies.

What Is The Ocrevus Market Growth Forecast?

The growth in the forecast period can be attributed to growing adoption of personalized ms treatment approaches, expansion of home and outpatient infusion services, rising investments in neuroimmunology research, increasing focus on slowing disease progression, development of next-generation monoclonal antibodies. Major trends in the forecast period include increasing use of monoclonal antibody therapies for ms, rising adoption of b-cell targeted treatments, expansion of infusion center-based care models, growing focus on long-term disease modification, enhanced patient monitoring and real-world evidence collection.

What Are The Drivers Of The Ocrevus Market?

The rise in multiple sclerosis is expected to drive the growth of the ocrevus market going forward. Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, where the immune system mistakenly attacks the protective myelin sheath of nerve fibers. The rise in multiple sclerosis (MS) cases is attributed to a combination of genetic, environmental, and lifestyle factors, including better diagnosis, increased awareness, and changes in diet and urban living. Ocrevus is used for multiple sclerosis (MS) to reduce disease activity, slow progression, and manage symptoms by targeting and depleting CD20-positive B-cells, which contribute to the immune-mediated damage in MS. For instance, in May 2024, according to the MS Society UK, a UK-based non-profit organization, over 150,000 people are living with MS in the UK as of 2024. The prevalence has increased by 15% in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Therefore, the rise in multiple sclerosis will drive the ocrevus industry. The growing focus on personalized medicine is expected to propel the growth of the ocrevus market going forward. Personalized medicine supports healthcare providers in creating tailored treatment plans and making informed treatment choices by utilizing a patient's genetic information to understand their disease. The focus on personalized medicine is rising due to its potential to enhance treatment effectiveness, reduce adverse effects, and address the growing demand for tailored healthcare solutions driven by advancements in genetic and diagnostic technologies. The focus on personalized medicine positively impacts Ocrevus by enabling its targeted treatment approach for multiple sclerosis, improving patient outcomes, and solidifying its position as a preferred therapeutic option. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, increasing personalized medicine is expected to drive the growth of the ocrevus industry.

How Will The Drivers Impact Growth In The Global Ocrevus Market?

• Rising Prevalence Of Multiple Sclerosis (MS) (High) – During the forecast period, the rising prevalence of multiple sclerosis (MS) is expected to become a key growth driver for the ocrevus market by 2030. The growing incidence of both relapsing and progressive forms of multiple sclerosis is expanding the eligible patient population requiring long-term disease-modifying treatment. Advances in neurological screening, wider availability of magnetic resonance imaging (MRI), and increasing recognition of early disease symptoms are supporting faster diagnosis and timely therapeutic intervention. As healthcare systems continue to prioritize comprehensive multiple sclerosis management, demand for established biologic therapies is expected to strengthen. • Increasing Preference For High-Efficacy Biologic Therapies (High) – During the forecast period, the increasing preference for high-efficacy biologic therapies is expected to emerge as a major factor driving the expansion of the ocrevus market by 2030. Physicians are increasingly adopting advanced biologic treatments for patients requiring sustained disease control and improved long-term clinical outcomes. Growing confidence in monoclonal antibody therapies, supported by evolving treatment recommendations and long-term safety evidence, is encouraging earlier use in appropriate patient populations. Continuous innovation in biologic drug development is also reinforcing the transition toward highly targeted therapies for neurological disorders. • Expansion Of Healthcare Access And Reimbursement Support (Medium) – During the forecast period, the expansion of healthcare access and reimbursement support is expected to act as a key growth catalyst for the ocrevus market by 2030. Broader insurance coverage, expanded public funding for specialty medicines, and improvements in reimbursement pathways are enabling greater access to advanced multiple sclerosis therapies. Healthcare providers are also expanding infusion services and specialty treatment networks to improve patient convenience and continuity of care. As healthcare accessibility continues to improve across developed and emerging markets, utilization of biologic therapies is expected to increase steadily.

How Will The Restraints Impact Growth In The Global Ocrevus Market?

• Risk of Adverse Events and Infection Concerns (High) – During the forecast period, risk of adverse events and infection concerns limits the growth of the Ocrevus market as the therapy suppresses B cells, potentially increasing susceptibility to infections and infusion-related reactions. Physicians often require comprehensive patient screening and ongoing monitoring before and during treatment to minimize safety risks. Concerns regarding immune suppression, opportunistic infections, and treatment-related complications may lead some healthcare providers to consider alternative therapies for certain patient populations. • Growing Competition from Emerging Multiple Sclerosis Therapies (High) – During the forecast period, growing competition from emerging multiple sclerosis therapies poses a restraint to the Ocrevus market as pharmaceutical companies continue to develop next-generation biologics, oral therapies, and innovative immune-modulating treatments. New products offering comparable efficacy, improved safety profiles, greater convenience, or less frequent monitoring requirements can influence physician prescribing patterns. The anticipated entry of biosimilars and novel disease-modifying therapies may also intensify pricing pressure and reduce Ocrevus' long-term market share. • High Treatment Costs And Reimbursement Challenges (Medium) – During the forecast period, high treatment costs and reimbursement challenges can act as a significant restraint on the Ocrevus market because biologic therapies involve substantial acquisition, administration, and long-term treatment expenses. The high cost of Ocrevus may limit patient access, particularly in countries with restricted healthcare budgets or inadequate insurance coverage. Variations in reimbursement policies and pricing negotiations across different healthcare systems can delay treatment initiation and reduce adoption. Healthcare providers and payers increasingly evaluate the cost-effectiveness of disease-modifying therapies before approving reimbursement, which may influence prescribing decisions. In addition, patient out-of-pocket expenses can discourage treatment adherence in certain markets. Consequently, high treatment costs and reimbursement challenges can limit market penetration and restrain the growth of the Ocrevus market.

Key Players In The Global Ocrevus Market

Major companies operating in the ocrevus market are F. Hoffmann-La Roche Ltd.

Global Ocrevus Market Trends and Insights

Major companies operating in the Ocrevus market are focusing on developing innovative solutions, such as subcutaneous combination formulations, to meet the rising demand for more convenient administration, improved treatment flexibility, and broadened access for multiple sclerosis patients. Subcutaneous formulations combine therapeutic monoclonal antibodies with absorption-enhancing agents to allow faster delivery and reduced infusion burden compared with traditional intravenous dosing that requires longer administration times in clinical settings. For instance, in September 2024, Genentech Inc., a US-based biotechnology company, announced that the United States Food and Drug Administration (U.S. FDA) had granted approval for Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only subcutaneous (SC) injection that healthcare professionals can administer twice a year, taking approximately 10 minutes per session. This groundbreaking approval provides individuals living with multiple sclerosis (MS) with more treatment options and greater flexibility for healthcare providers to tailor care to meet the unique needs of each patient.

What Defines the Ocrevus Market?

The ocrevus market consists of sales of monoclonal antibodies, cancer therapies, infusion delivery systems and research and development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ocrevus Market Report 2026?

The ocrevus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ocrevus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.